Pareen J. Shenoy

Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States

Peripheral T-cell lymphomas (PTCL) represent a small subgroup of non-Hodgkin lymphomas historically difficult to diagnose. We conducted a comprehensive assessment of 3287 PTCL cases diagnosed from 1992 to 2005 in 13 Surveillance, Epidemiology and End Results registries. Incidence trends, age-adjusted incidence rates and relative survival rates were compared across the study period, and by sex, race and age groups. From 1992 to 2005, PTCL incidence increased by 280%. Age-adjusted incidence rates were higher in males (Male/Female incidence rate ratio (IRR) 1.8) and in Blacks (Black/White IRR 1.2). Asian predominance was pronounced for extranodal NK/T-cell lymphoma, nasal type. Whites had higher 5-year survival than other racial groups for most histologic subtypes; however, the differences were not statistically significant. The variance in incidence rates and outcomes across PTCL subtypes support the pursuit of ongoing research to identify the etiology, pathophysiology, treatment patterns and differences in treatment response for PTCL subsets.

Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States†

Diffuse large B‐cell lymphoma (DLBCL) is often cured with standard chemoimmunotherapy, but there is great heterogeneity in presentation and outcomes.

Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population

BackgroundBreast magnetic resonance imaging (MRI) is a sensitive method of breast imaging virtually uninfluenced by breast density. Because of the improved sensitivity, breast MRI is increasingly being used for detection of breast cancer among high risk young women. However, the specificity of breast MRI is variable and costs are high. The purpose of this study was to determine if breast MRI is a cost-effective approach for the detection of breast cancer among young women at high risk.MethodsA Markov model was created to compare annual breast cancer screening over 25 years with either breast MRI or mammography among young women at high risk. Data from published studies provided probabilities for the model including sensitivity and specificity of each screening strategy. Costs were based on Medicare reimbursement rates for hospital and physician services while medication costs were obtained from the Federal Supply Scale. Utilities from the literature were applied to each health outcome in the model including a disutility for the temporary health state following breast biopsy for a false positive test result. All costs and benefits were discounted at 5% per year. The analysis was performed from the payer perspective with results reported in 2006 U.S. dollars. Univariate and probabilistic sensitivity analyses addressed uncertainty in all model parameters.ResultsBreast MRI provided 14.1 discounted quality-adjusted life-years (QALYs) at a discounted cost of

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.

18,167 while mammography provided 14.0 QALYs at a cost of

Incidence Patterns and Outcomes for Hodgkin Lymphoma Patients in the United States

4,760 over 25 years of screening. The incremental cost-effectiveness ratio of breast MRI compared to mammography was

Incidence and survival patterns of cutaneous T-cell lymphomas in the United States

179,599/QALY. In univariate analysis, breast MRI screening became <

Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States

50,000/QALY when the cost of the MRI was <

Prescription Opioid Usage and Abuse Relationships: An Evaluation of State Prescription Drug Monitoring Program Efficacy

315. In the probabilistic sensitivity analysis, MRI screening produced a net health benefit of -0.202 QALYs (95% central range: -0.767 QALYs to +0.439 QALYs) compared to mammography at a willingness-to-pay threshold of

Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?

50,000/QALY. Breast MRI screening was superior in 0%, <

Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma

50,000/QALY in 22%, >